Buserelin-depot in the treatment of prostate cancer

The high incidence of prostate cancer (PC) and the considerably wide use of hormone therapy for its treatment as an individual modality
for its advanced forms (Т3–Т4, N1, M1), recurrences, and progression after local treatments (radical prostatectomy, radiation therapy) and for combined treatment as neoadjuvant and adjuvant therapies determine the importance of a sufficient range of hormonal drugs at an urologic oncologist’s disposal. Among the luteinizing hormone-releasing hormone (LHRH) agonists, there is rather long-known Buserelin made in Russia, the clinical efficacy of which is highly competitive with foreign analogs. The paper presents the results of a 3-month trial of the efficiency and safety of Buserelin depot treatment in 20 patients aged 53 to 87 years with morphologically verified PC. The patients with PC showed a gradual decrease in the mean values of prostate-specific antigen (PCA) from
81.2 to 27.8 and 23.0 ng / ml at 2 and 3 months of Buserelin depot therapy, respectively. The performed therapy could achieve reductions in testosterone levels from 168 ng / dl at baseline to 21 and 19.8 ng / dl postcastration at 1 and 3 months of the therapy.
All the patients tolerated Buserelin depot therapy without having clinically significant adverse reactions. The most common complaints were hyperhidrosis and hot flushes, which are typical of all LHRH agonists and which are not marked in the treatment with other drugs of this group.

Conclusion. Buserelin depot 3.75 mg is a highly effective Russian drug to treat hormone-dependent PC. Its administration causes a reduction in PSA levels and ensures a steady decline in serum testosterone concentrations to the postcastration level without causing serious side effects. The findings do not differ from those when foreign LHRH analogues are used.

1. Anderson J., Abrahamsson P.A., Crawford D. et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int 2008;101: 1497–501.

2. Heidenreich A., Pfister D., Ohlamann C.H. et al. Androgen deprivation for advanced prostate cancer. Urologe 2008;47:270– 83.

3. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.А. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. [Malignant neoplasms in Russia in 2012 (morbidity and mortality). Eds. by A.D. Kaprin, V.V. Starinsky, G.A. Petrova. M.: FSBE “P.A. Hertzen Moscow Cancer Research Institute” of the Ministry of Health of Russia, 2014. (In Russ.)].

4. Мишугин С.В., Мордовин А.А., Грицкевич А.А., Русаков И.Г. Медикаментозная кастрация в лечении распространенных форм рака предстательной железы. Роль бусерелина. Медицинский совет 2014;8:3–6. [Mishugin S.V., Mordovin A.A., Gritskevich A.A., Rusakov I.G. Medical Castration in Treatment of Most Distributed Forms of Prostate Cancer. Role of Buserelin. Medical Council (Meditsinskiy Sovet) 2014;8:3–6.(In Russ.)].

5. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013. Kaprin A.D., Starinskiy V.V., Petrova G.V. Status of Oncology Aid to the Population of Russia in 2012. Moscow, 2013. (In Russ.)].

6. Бабаев Р., Матвеев В.Б., Волкова М.И. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология 2011;2:78–83. [Babayev R., Matveyev V.B., Volkova M.I. Factors of Survival Prediction of Patients with Advanced Prostate Cancer That Receive Hormone Therapy. Oncourology (Onkourologiya) 2011;(2):78–83.(In Russ.)].

7. Нюшко К.М., Алексеев Б.Я., Калпинский А.С., Каприн А.Д. Антагонисты лютеинизирующего гормона рилизинг-гормона у больных раком предстательной железы. Стандартный подход и результаты инновационных исследований. Онкоурология 2014;4:70–4. [Nyushko K.M., Alexeev B.Y., Kalpinsky A.S., Kaprin A.D. Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. Standard approach and results of innovational studies. Onkourologiya = Oncourology 2014;4:70–4. (In Russ.)].

8. Рапопорт Л.М., Демидко Ю.Л. Применение бусерелина-депо – агониста гонадотропин-рилизинг-гормона в лечении рака простаты. Андрология и генитальная хирургия 2014;3:2–7. [Rapoport L.M., Demidko Yu.L. Application of Buserelin- Depo: Agonist of Gonadotropin Releasing Hormone in Treatment of Prostate Cancer. Andrology and Genital Surgery (Andrologiya i Genitalnaya Khirurgiya) 2014;3:2–7. (In Russ.)].

9. Сивков А.В., Матвеев В.Б., Бухаркин Б.В. и др. Результаты длительного применения агониста гонадотропин-рилизинг-гормона бусерелина-депо у больных раком предстательной железы. Consilium Medicum 2005;7(7):591–5. [Sivkov A.V., Matveyev V.B., Bukharkin B.V., et al. Results of Long-Term Application of Agonist of Gonadotropin Releasing Hormone of Buserelin-Depo of Patients with Prostate Cancer. Consilium Medicum 2005;7(7):591–5. (In Russ.)].

10. Копыльцов Е.И., Леонов О.В., Кривоногов И.И. и др. Отечественный депонированный лекарственный препарат в лечении больных раком предстательной железы. Онкоурология 2005. Тезисы 6-й Всерос. научно-практ. конференции «Актуальные вопросы лечения онкоурологических заболеваний». С. 94–5. [Kopyltsov E.I., Leonov O.V., Krivonogov I.I., et al. Domestic Deposited Drug in Treatment of Patients with Prostate Cancer. Oncourology (Onkourologiya) 2005. Abstracts of the 6th All-Russian Scientific Conference “Actual Problems of Treatment of Oncourological Diseases”. pp. 94–95. (In Russ.)].